Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: A randomized, double-blind, double-dummy, crossover study

Headache

Volumn 43, Issue 8, 2003, Pages 845-852

  Stronks, Dirk L ^a   Tulen, Joke H M ^a   Bussmann, Hans B J ^a   Mulder, Laus J M M ^b   Passchier, Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

Author keywords

Acute antimigraine therapy; Ambulatory accelerometry; Daily activities; Mood; Naproxen; Naratriptan

Indexed keywords

ANTIMIGRAINE AGENT; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ACCELEROMETER; ADULT; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEADACHE; HUMAN; MIGRAINE; MOBILIZATION; MOOD; NAUSEA; PHOBIA; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; TASK PERFORMANCE; VOMITING;

ACTIVITIES OF DAILY LIVING; ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; INDOLES; MIDDLE AGED; MIGRAINE DISORDERS; NAPROXEN; PIPERIDINES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0042738115     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03162.x     Document Type: Article

References (46)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):10-73.
2. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994;34(suppl 2):6-11.
3. Blau J. The clinical diagnosis of migraine. J Neurol. 1991;238:S6-S11.
4. Göbel H, Krapat S. Psychological status during migraine attack and interval before and after treatment with a selective 5-HT1 agonist. Headache. 1993;33:118-120.
5. Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. Headache. 1994;34:344-350.
6. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache. 1995;35:330-337.
7. Cavallini A, Micieli G, Bussone G, Rossi F, Nappi G. Headache and quality of life. Headache. 1995;35:29-35.
8. Micieli G, Frediani F, Cavallini A, et al. Quantification of headache disability: a diagnostic-based approach. Headache. 1995;35:131-137.
9. Haks M, Sorbi M, Passchier J. Neglected symptoms of a migraine attack [letter]. Headache. 1997;37:115.
10. Dowson A, Jagger S. The UK patient survey: quality of life and treatment. Curr Med Res Opin. 1999;15:241-253.
11. Tulen JH, Stronks DL, Bussmann JB, Pepplinkhuizen L, Passchier J. Towards an objective quantitative assessment of daily functioning in migraine: a feasibility study. Pain. 2000;86:139-149.
12. Bigal ME, Bigal JM, Betti M, Bordini CA, Speciali JG. Evaluation on the impact of migraine and episodic tension-type headache on the quality of life and performance of a university student population. Headache. 2001;41:710-719.
13. Passchier J, Mourik J, Brienen JA, Hunfeld JA. Cognitions, emotions, and behavior of patients with migraine when taking medication during an attack. Headache. 1998;38:458-464.
14. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29-35.
15. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics. 1997;11(suppl 1):1-10.
16. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology. 1998;50:1741-1745.
17. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States. Disability and economic costs. Arch Intern Med. 1999;159:813-818.
18. Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of headache. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. Oxford: University Press; 2001:85-108.
19. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics. 1995;7:170-179.
20. Bussmann JB, Reuvekamp PJ, Veltink PH, Martens WL. Validity and reliability of measurements obtained with an 'activity monitor' in people with and without a transtibial amputation. Phys Ther. 1998a;78:989-998.
21. Bussmann JB, Tulen JH, Herel EC, Stam HJ. Quantification of study. Psychophysiology. 1998;35:488-496.
22. Bussmann JB, Laar YM, Neeleman MP, Stam HJ. Ambulatory accelerometry to quantify motor behaviour in patients after failed back surgery: a validation study. Pain. 1998;74:153-161.
23. Berg van den HJ, Bussmann JB, Balk AH, Stam H. Validity of ambulatory accelerometry to quantify physical activity in heart failure. Scand J Rehab Med. 2000;32:187-192.
24. Bussmann JB, Martens WL, Tulen JH, Schasfoort FC, Berg-Emons HJ, Stam HJ. Measuring daily behavior using ambulatory accelerometry: the Activity Monitor. Behav Res Methods Instrum Comput. 2001;33:349-356.
25. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia. 1985;5:115-119.
26. Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia. 1985;5:107-112.
27. Nestvold K. Naproxen and naproxen sodium in acute migraine attacks. Cephalalgia. 1986;6(suppl 4):81-84.
28. Larsen BH, Christiansen LV, Andersen B, Olesen J. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990;81:464-467.
29. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12:169-171.
30. Dahlof C, Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993;13:117-123.
31. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicyclic acid and placebo. Cephalalgia. 1995;15:531-535.
32. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache. 1997;37:640-645.
33. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology. 1997;49:1485-1490.
34. Bates D, Winter P. Efficacy and tolerability of naratriptan tablets (0.1 mg-2.5 mg) in the acute treatment of migraine. Eur J Neurol. 1998;5(suppl 3):S48-S49.
35. Bussmann JB, Hartgerink I, Woude van der LH, Stam HJ. Measuring physical strain during ambulation with accelerometry. Med Sci Sports Exerc. 2000;32:1462-1471.
36. Wald FD, Mellenberg GJ. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States. [The shortened version of the Dutch translation of The Profile of Mood States.] Ned Tijdschr Psychol. 1990;45:86-90.
37. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement W. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431-436.
38. Keppel G. Design and Analysis. A Researcher's Handbook. Englewood Cliffs, NJ: Prentice Hall, Inc; 1973.
39. Pini LA, Bertolotti M, Trenti T, Vitale G. Disposition of naproxen after oral administration during and between migraine attacks. Headache. 1993;33:191-194.
40. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of Rizatriptan 10 mg vs. Naratriptan 2.5 mg in Migraine. Eur Neurol. 1999;42:173-179.
41. Havanka H, Dahlof C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Clin Ther. 2000;22:970-980.
42. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. Oxford: University Press; 2001:121-237.
43. Stronks DL, Tulen JH, Bussmann JB, Mulder LJ, Passchier J. Interictal daily functioning in migraine. Cephalalgia. In press.
44. Vendrig AA, Lousberg R. Within-person relationships among pain intensity, mood and physical activity in chronic pain: a naturalistic approach. Pain. 1997;73:71-76.
45. Fordyce WE, Lansky D, Calsyn DA, Shelton JL, Stolov WC, Rock DL. Pain measurement and pain behavior. Pain. 1984;18:53-69.
46. Holroyd KA, Malinoski P, Davis MK, Lipchik GL. The three dimensions of headache impact: pain, disability and affective distress. Pain. 1999;83:571-578.